Related Experiment Video

Updated: Jul 31, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N

A Yakkundi1, V McErlane, M Murray

  • 1Biomedical Sciences Research Institute, University of Ulster, Coleraine, UK.

Cancer Gene Therapy
|January 18, 2006
PubMed

Insights

Gene therapy using cytochrome P450 1A1 (CYP1A1) effectively activates the bioreductive prodrug AQ4N in hypoxic tumors. This approach enhances radiosensitization and significantly delays tumor regrowth, offering a promising strategy for cancer treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Hypoxic tumors are resistant to conventional therapies.
  • Bioreductive prodrugs activated by specific enzymes offer targeted cancer treatment.
  • Cytochrome P450s (CYPs) can metabolize prodrugs like AQ4N into active cytotoxins.

Purpose of the Study:

  • To investigate the efficacy of CYP1A1 in metabolizing AQ4N for cancer therapy.
  • To evaluate the potential of CYP1A1-mediated gene-directed enzyme prodrug therapy (GDEPT) for radiosensitization.

Main Methods:

  • AQ4N metabolism by various CYP isoforms was assessed using liver microsomes.
  • CYP1A1 gene transfection was performed in hypoxic RIF-1 mouse cells in vitro.
  • DNA damage was evaluated using the alkaline comet assay.
  • In vivo studies involved intra-tumoral injection of CYP1A1 constructs with AQ4N and radiation.

Main Results:

  • CYP1A1 demonstrated highly efficient metabolism of AQ4N.
  • Transfection of CYP1A1 in hypoxic cells significantly increased DNA damage.
  • In vivo, CYP1A1 combined with AQ4N and radiation delayed tumor regrowth by 16 days.

Conclusions:

  • CYP1A1 is an effective enzyme for bioreducing AQ4N to a cytotoxic agent.
  • CYP1A1-mediated GDEPT is a viable strategy to enhance radiosensitization and inhibit tumor growth in hypoxic environments.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...